Spinocerebellar ataxia type 1

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter discusses the pathogenesis, pathology, and pathophysiology of spinocerebellar ataxia type 1 (SCA1), along with mechanisms of disease recovery. The clinical features seen in patients with SCA1 usually include ataxia, dysarthria, and bulbar dysfunction. SCA1 appears to have a defined neuropathological pattern that separates it from other dominantly inherited ataxias and from sporadic entities such as multiple system atrophy. The disease-causing mutation is expansion of an unstable CAG trinucleotide repeat within the coding region of the gene. Disease is caused by the expansion of this repeat producing an expanded tract of glutamine amino acids within the SCA1 gene product, ataxin-1. SCA1 pathogenesis is induced by some toxic function gained by the mutant polyglutamine protein as a result of the expanded glutamine tract. Polyglutamine expansion seems to cause mutant ataxin-1 to adopt an altered folding state, leading to its ubiquitination, aggregation, and resistance to proteasomal degradation. Over the course of the disease, the aggregated protein may in turn contribute to disease progression by altering the turnover of other critical proteins that may encumber the ubiquitin-proteasome system. The chapter also presents an experimental mouse model that examines the capacity of Purkinje neurons to recover from the adverse effects of ataxin-1. Results suggest that Purkinje cells have a sustained ability to recover from long-term effects of mutant ataxin-1. A therapeutic intervention targeted at reducing the expression of mutant ataxin-1 showed that SCA1 RNAi was effective in suppressing Purkinje cell pathology and neurological signs when SCA1 mice were injected with SCA1 RNAi at 7 weeks of age.

Original languageEnglish (US)
Title of host publicationNeurobiology of Disease
PublisherElsevier Inc.
Pages149-155
Number of pages7
ISBN (Print)9780120885923
DOIs
StatePublished - Dec 1 2007

Fingerprint

Spinocerebellar Ataxias
Purkinje Cells
Ataxia
RNA Interference
Glutamine
Pathology
Multiple System Atrophy
Trinucleotide Repeats
Dysarthria
Poisons
Ubiquitination
Proteasome Endopeptidase Complex
Mutant Proteins
Ubiquitin
Genes
Disease Progression
Proteins
Theoretical Models
Ataxin-1
Amino Acids

Cite this

Orr, H. T. (2007). Spinocerebellar ataxia type 1. In Neurobiology of Disease (pp. 149-155). Elsevier Inc.. https://doi.org/10.1016/B978-012088592-3/50015-3

Spinocerebellar ataxia type 1. / Orr, Harry T.

Neurobiology of Disease. Elsevier Inc., 2007. p. 149-155.

Research output: Chapter in Book/Report/Conference proceedingChapter

Orr, HT 2007, Spinocerebellar ataxia type 1. in Neurobiology of Disease. Elsevier Inc., pp. 149-155. https://doi.org/10.1016/B978-012088592-3/50015-3
Orr HT. Spinocerebellar ataxia type 1. In Neurobiology of Disease. Elsevier Inc. 2007. p. 149-155 https://doi.org/10.1016/B978-012088592-3/50015-3
Orr, Harry T. / Spinocerebellar ataxia type 1. Neurobiology of Disease. Elsevier Inc., 2007. pp. 149-155
@inbook{033d0a8a94e143ef88446b161288c7de,
title = "Spinocerebellar ataxia type 1",
abstract = "This chapter discusses the pathogenesis, pathology, and pathophysiology of spinocerebellar ataxia type 1 (SCA1), along with mechanisms of disease recovery. The clinical features seen in patients with SCA1 usually include ataxia, dysarthria, and bulbar dysfunction. SCA1 appears to have a defined neuropathological pattern that separates it from other dominantly inherited ataxias and from sporadic entities such as multiple system atrophy. The disease-causing mutation is expansion of an unstable CAG trinucleotide repeat within the coding region of the gene. Disease is caused by the expansion of this repeat producing an expanded tract of glutamine amino acids within the SCA1 gene product, ataxin-1. SCA1 pathogenesis is induced by some toxic function gained by the mutant polyglutamine protein as a result of the expanded glutamine tract. Polyglutamine expansion seems to cause mutant ataxin-1 to adopt an altered folding state, leading to its ubiquitination, aggregation, and resistance to proteasomal degradation. Over the course of the disease, the aggregated protein may in turn contribute to disease progression by altering the turnover of other critical proteins that may encumber the ubiquitin-proteasome system. The chapter also presents an experimental mouse model that examines the capacity of Purkinje neurons to recover from the adverse effects of ataxin-1. Results suggest that Purkinje cells have a sustained ability to recover from long-term effects of mutant ataxin-1. A therapeutic intervention targeted at reducing the expression of mutant ataxin-1 showed that SCA1 RNAi was effective in suppressing Purkinje cell pathology and neurological signs when SCA1 mice were injected with SCA1 RNAi at 7 weeks of age.",
author = "Orr, {Harry T}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/B978-012088592-3/50015-3",
language = "English (US)",
isbn = "9780120885923",
pages = "149--155",
booktitle = "Neurobiology of Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Spinocerebellar ataxia type 1

AU - Orr, Harry T

PY - 2007/12/1

Y1 - 2007/12/1

N2 - This chapter discusses the pathogenesis, pathology, and pathophysiology of spinocerebellar ataxia type 1 (SCA1), along with mechanisms of disease recovery. The clinical features seen in patients with SCA1 usually include ataxia, dysarthria, and bulbar dysfunction. SCA1 appears to have a defined neuropathological pattern that separates it from other dominantly inherited ataxias and from sporadic entities such as multiple system atrophy. The disease-causing mutation is expansion of an unstable CAG trinucleotide repeat within the coding region of the gene. Disease is caused by the expansion of this repeat producing an expanded tract of glutamine amino acids within the SCA1 gene product, ataxin-1. SCA1 pathogenesis is induced by some toxic function gained by the mutant polyglutamine protein as a result of the expanded glutamine tract. Polyglutamine expansion seems to cause mutant ataxin-1 to adopt an altered folding state, leading to its ubiquitination, aggregation, and resistance to proteasomal degradation. Over the course of the disease, the aggregated protein may in turn contribute to disease progression by altering the turnover of other critical proteins that may encumber the ubiquitin-proteasome system. The chapter also presents an experimental mouse model that examines the capacity of Purkinje neurons to recover from the adverse effects of ataxin-1. Results suggest that Purkinje cells have a sustained ability to recover from long-term effects of mutant ataxin-1. A therapeutic intervention targeted at reducing the expression of mutant ataxin-1 showed that SCA1 RNAi was effective in suppressing Purkinje cell pathology and neurological signs when SCA1 mice were injected with SCA1 RNAi at 7 weeks of age.

AB - This chapter discusses the pathogenesis, pathology, and pathophysiology of spinocerebellar ataxia type 1 (SCA1), along with mechanisms of disease recovery. The clinical features seen in patients with SCA1 usually include ataxia, dysarthria, and bulbar dysfunction. SCA1 appears to have a defined neuropathological pattern that separates it from other dominantly inherited ataxias and from sporadic entities such as multiple system atrophy. The disease-causing mutation is expansion of an unstable CAG trinucleotide repeat within the coding region of the gene. Disease is caused by the expansion of this repeat producing an expanded tract of glutamine amino acids within the SCA1 gene product, ataxin-1. SCA1 pathogenesis is induced by some toxic function gained by the mutant polyglutamine protein as a result of the expanded glutamine tract. Polyglutamine expansion seems to cause mutant ataxin-1 to adopt an altered folding state, leading to its ubiquitination, aggregation, and resistance to proteasomal degradation. Over the course of the disease, the aggregated protein may in turn contribute to disease progression by altering the turnover of other critical proteins that may encumber the ubiquitin-proteasome system. The chapter also presents an experimental mouse model that examines the capacity of Purkinje neurons to recover from the adverse effects of ataxin-1. Results suggest that Purkinje cells have a sustained ability to recover from long-term effects of mutant ataxin-1. A therapeutic intervention targeted at reducing the expression of mutant ataxin-1 showed that SCA1 RNAi was effective in suppressing Purkinje cell pathology and neurological signs when SCA1 mice were injected with SCA1 RNAi at 7 weeks of age.

UR - http://www.scopus.com/inward/record.url?scp=84883906159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883906159&partnerID=8YFLogxK

U2 - 10.1016/B978-012088592-3/50015-3

DO - 10.1016/B978-012088592-3/50015-3

M3 - Chapter

SN - 9780120885923

SP - 149

EP - 155

BT - Neurobiology of Disease

PB - Elsevier Inc.

ER -